

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

CHANGE OF DIRECTORS AND RESIGNATION OF CHIEF EXECUTIVE OFFICER AND CHANGE OF AUTHORISED REPRESENTATIVE

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER AND CHANGE OF AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 16 September 2022:

Mr. Luo Chunyi (“**Mr. Luo**”) has resigned as an executive Director and the chief executive officer of the Company as well as the authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in order to devote more time to his other personal commitments.

Mr. Luo confirmed that he has no disagreement with the Board in any respect and that there are no matters that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”) in relation to his resignation.

Following the resignation of Mr. Luo, Mr. Li Xinzhou (“**Mr. Li**”), the chairman of the Board and an executive Director, has been appointed as the Authorised Representative, with effect from 16 September 2022.

The Board would like to express its sincere gratitude to Mr. Luo for his contribution to the Company during his tenure of office at the Board.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board announces that with effect from 16 September 2022, Mr. Yang Yuewen (“**Mr. Yang**”) has been appointed as an executive Director.

The biographical details of Mr. Yang are set out below:

Yang Yuewen, aged 34, is our chief operating officer. Mr. Yang joined the Company in September 2016 and worked as a product manager and marketing manager of the AW business unit from September 2016 to September 2019. In October 2019, he was appointed as the general manager of the AW business unit of the Company and was responsible for the promotion and sales of Alfa Sigma’s products and NovaBay’s products of the Group. Prior to joining the Company, Mr. Yang worked at Novartis Pharma Limited and AstraZeneca Pharma Limited. Mr. Yang graduated from Jiangxi University of Chinese Medicine with a bachelor’s degree in pharmaceutical engineering in June 2010 and graduated from Jiangxi University of Chinese Medicine with a master’s degree in pharmaceutical chemistry in June 2013 (the major was a joint training program between China State Institute of Pharmaceutical Industry and Jiangxi University of Chinese Medicine). He was appointed as the chief operating officer of the Company on 31 December 2021.

Mr. Yang has entered into a service contract with the Company for a term of three years commencing from 16 September 2022 and his appointment is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the service contract, Mr. Yang will receive a remuneration of RMB720,000 per year from the Company which was determined with reference to his duties and responsibilities in the Group and the market rate for the position.

Save as disclosed above, as at the date of this announcement, Mr. Yang has confirmed that (i) he does not hold any other positions in the Group; (ii) he has no relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders (as such terms are defined in the Listing Rules) of the Company; (iii) he has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iv) he is not interested (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong)) in the shares or any securities of the Company; and (v) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and he is not aware of any other matters in relation to his appointment that need to be brought to the attention of the Stock Exchange and the Shareholders.

The Board would like to extend a warm welcome to Mr. Yang in joining of the Board.

By Order of the Board
China Pioneer Pharma Holdings Limited
LI Xinzhou
Chairman

Hong Kong, 16 September 2022

As at the date of this announcement, the Directors are Mr. LI Xinzhou, Mr. XIAO Guoguang and Mr. YANG Yuewen as executive Directors, Ms. HU Mingfei as non-executive Director and Mr. ZHANG Hong, Mr. WONG Chi Hung, Stanley and Mr. LAI Chanshu as independent non-executive Directors.